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OBJECTIVES: To comprehensively classify interventions performed by 
emergency medicine clinical pharmacists and quantify cost avoidance 
generated through their accepted interventions.
DESIGN: A multicenter, prospective, observational study was performed 
between August 2018 and January 2019.
SETTING: Community and academic hospitals in the United States.
PARTICIPANTS: Emergency medicine clinical pharmacists.
INTERVENTIONS: Recommendations classified into one of 38 interven-
tion categories associated with cost avoidance.
MEASUREMENTS AND MAIN RESULTS: Eighty-eight emergency 
medicine pharmacists at 49 centers performed 13,984 interventions 
during 917 shifts that were accepted on 8,602 patients and generated 
$7,531,862 of cost avoidance. The quantity of accepted interventions 
and cost avoidance generated in six established categories were as fol-
lows: adverse drug event prevention (1,631 interventions; $2,225,049 
cost avoidance), resource utilization (628; $310,582), individualization 
of patient care (6,122; $1,787,170), prophylaxis (24; $22,804), hands-on 
care (3,533; $2,836,811), and administrative/supportive tasks (2,046; 
$342,881). Mean cost avoidance was $538.61 per intervention, $875.60 
per patient, and $8,213.59 per emergency medicine pharmacist shift. The 
annualized cost avoidance from an emergency medicine pharmacist was 
$1,971,262. The monetary cost avoidance to pharmacist salary ratio was 
between $1.4:1 and $10.6:1.
CONCLUSIONS: Pharmacist involvement in the care of patients present-
ing to the emergency department results in significant avoidance of health-
care costs, particularly in the areas of hands-on care and adverse drug 
event prevention. The potential monetary benefit-to-cost ratio for emer-
gency medicine pharmacists is between $1.4:1 and $10.6:1.
KEY WORDS: cost; medical care; medication; pharmacist; safety; value
Patient visits to emergency departments (EDs) in the United States totaled almost 137 million in 2015 (1). Over the last few decades, emer-gency medicine (EM) teams that typically consisted of physicians and 
nurses have evolved to incorporate other professions, including pharmacists. 
Traditionally, pharmacists began their careers immediately after pharmacy 
school or 1 year of postgraduate residency training, whereas current EM phar-
macists frequently have completed specialty residency or fellowship training 
and are board certified. Subsequently, the role of pharmacists in the care of 
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ED patients has shifted from verifying, preparing, 
and dispensing medications in a remote location to 
performing direct, bedside patient care as a member 
of the EM multidisciplinary team (2). EM pharma-
cists are required to call upon knowledge pertaining 
to pharmacology ranging from pediatrics to geriatrics 
and critical care to primary care, which has resulted 
in improved outcomes in numerous populations 
and hospital structures (2–11). Consequently, mul-
tiple professional healthcare organizations, including 
the American College of Emergency Physicians and 
American College of Medical Toxicology, consider 
EM pharmacists to be essential healthcare providers 
(10–12). Despite these endorsements, a 2016 survey 
of characterizing EM pharmacist services found that 
over half of EDs employed EM pharmacists 12 hours 
per day or less, suggesting that EM pharmacists remain 
widely underutilized (13).
Previous studies of interventions performed by 
EM pharmacists have focused on adverse drug event 
(ADE) prevention and reductions in medication use 
and costs (3, 8, 9, 14). While these studies have made 
important steps toward establishing the value an EM 
pharmacist brings to patient care, they are limited in 
size and scope and document interventions in a heter-
ogeneous manner not based on a rigorous framework. 
The only contemporary study to use a framework for 
cost avoidance (CA) from pharmacist interventions 
evaluated a medical ICU pharmacist’s clinical activi-
ties over a 12-month period and determined the CA of 
those activities exceeded $3 million with a benefit-cost 
ratio of 24.5:1 (15). However, these findings may not be 
generalizable to the ED as the composition of interven-
tions and practice culture differ greatly. The purposes 
of this study were to comprehensively classify inter-
ventions performed by EM pharmacists and quantify 
CA generated through accepted interventions.
METHODS
Study Design
The PHarmacist Avoidance or Reductions in Medical 
costs in patients presenting the EMergency Department 
study was a multicenter, prospective, observational 
study performed across the United States in commu-
nity and academic hospitals between August 2018 and 
January 2019. Recruitment was conducted via direct 
electronic mail with invitations sent to the Society of 
Critical Care Medicine’s (SCCM) Clinical Pharmacy and 
Pharmacology section listserv. From this listserv, which 
includes multiple healthcare professionals in addition to 
pharmacists, clinical pharmacists who provided direct 
(at the bedside) or decentralized (not directly within the 
ED) patient care for ED patients were invited to partic-
ipate. Pharmacists currently completing residency or 
fellowship training were not eligible for study partici-
pation. Multiple pharmacists from the same institution 
were eligible to participate. No minimum or maximum 
duration of study participation by each pharmacist was 
required so as to maximize data capture for pharmacist 
interventions; however, participants were encouraged 
to document interventions for 20 shifts. Only interven-
tions made by a pharmacist for patients residing in an 
ED were eligible for study inclusion.
Data Collection
In preparation for this study, a comprehensive, evi-
dence-based framework for categorizing and monetizing 
CA interventions by critical care and EM pharmacists 
was developed by our group a priori and previously 
published (16). This framework contained 38 interven-
tions associated with CA that pharmacists can perform 
in the ICU and ED settings. Each intervention category 
was grouped into one of six intervention sections: ADE 
prevention, resource utilization, individualization of pa-
tient care, prophylaxis, hands-on care, and administrative 
and supportive tasks (Supplemental Table 1, http://links.
lww.com/CCX/A595). All clinical interventions made 
by participating pharmacists, regardless of their accept-
ance by the healthcare team, were recorded in Research 
Electronic Data Capture (Version 6.18.1, 2019; Vanderbilt 
University, Nashville, TN) (17). All participants received 
training on appropriate documentation of interventions 
using the CA framework. Interventions were entered at 
the patient level by each individual pharmacist. Each in-
tervention could only be documented in one intervention 
category; however, if multiple interventions were con-
ducted in a given patient, pharmacists were encouraged 
log each intervention. Pharmacists were encouraged to 
enter these data in real time to provide the most accu-
rate accounting of interventions. Although all interven-
tions (accepted and not accepted) were captured, only 
interventions accepted and implemented by the medical 
team were included in the CA analysis. Any interven-
tion unable to be classified was not recorded or avail-
able for study inclusion. Rush University Medical Center, 
Original Clinical Report
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the central and coordinating institutional review board 
(IRB), reviewed and approved this study (IRB number 
18021508-IRB01). This study was endorsed by the SCCM 
Discovery Network and was a work product of the SCCM 
Clinical Pharmacy and Pharmacology Section.
Study Outcomes and Statistical Analysis
The primary outcomes were the quantity, type, and ac-
ceptance of interventions provided by and the poten-
tial CA generated from clinical pharmacists practicing 
in ED settings. CA values overall and per patient were 
calculated by summing the CA for each intervention 
based on values from our previously published system-
atic framework and expressed in 2019 U.S. dollars (16). 
This framework, developed through a scoping review 
of the literature for interventions that could be per-
formed by ICU and/or ED pharmacists, standardizes 
the capture of pharmacist interventions in this setting 
and includes CA data for each type of intervention 
based on controlled and observational studies, as well 
as expert opinion. A sensitivity analysis was conducted 
to evaluate CA from those interventions we previ-
ously identified with the highest quality of evidence 
(evidence from well-designed controlled trials with 
or without randomization) according to the Grading 
of Recommendations, Assessment, Development, 
and Evaluation evidence-to-decision framework (18). 
These interventions included the following: 1) medica-
tion route: IV to oral conversion (resource utilization 
section), 2) medication route: hypertensive crisis man-
agement (resource utilization), 3) antimicrobial therapy 
initiation and streamlining (individualization of pa-
tient care), 4) change venous thromboembolism pro-
phylaxis to most appropriate agent (prophylaxis), and 
5) initiation of venous thromboembolism prophylaxis 
(prophylaxis) (16). Demographic data were collected 
on each pharmacist and institution. Patients were cat-
egorized according to Emergency Severity Index (ESI).
Data were characterized using descriptive statistics. 
The CA per pharmacist shift value was annualized using 
240 shifts, corresponding to five shifts per week for 48 
weeks, allowing for personal time off and holidays. This 
annualized CA for a pharmacist was compared with the 
average pharmacist salary and benefits not including 
overhead ($185,470) to calculate a monetary CA to phar-
macist salary ratio (19). Analyses were performed in Stata 
(Version 16; StataCorp LLC, College Station, TX).
RESULTS
One-hundred twenty-four pharmacists responded to 
our invitation to participate, with 88 pharmacists sub-
sequently participating in the study. During the study 
period, these 88 pharmacists at 49 centers across the 
United States completed 917 shifts. The mean ED visits 
per year at participating hospitals was 75,226 (sd 32,399). 
Pharmacists most frequently had been in practice for 
1–3 years (40.9%) and were board certified (72.7%). EM 
pharmacists spent the majority of their shift providing 
direct patient care (median, 6 hr; interquartile range 
[IQR], 4–8 hr) incorporating prospective order verifi-
cation into their shifts for a median of 5.5 hours (IQR, 
1–9 hr). Most shift lengths were 8 hours (43.1%) or 10 
hours (36.8%). EM pharmacists infrequently rounded 
with a multidisciplinary clinical service (17.4%) but 
rather spent a majority of time providing bedside serv-
ices in the ED. The median number of shifts was 17 
(IQR, 6–20), with significant variability in the number 
of patients each EM pharmacist-provided care for per 
shift (median, 55; IQR, 30–100). Patient acuity was 
most commonly ESI levels 2 or 3 (Table 1).
Of the 14,345 interventions made by EM pharma-
cists, 13,984 (97.4%) were accepted and implemented 
by the medical team. These 13,984 interventions were 
performed on 8,602 patients in six sections: ADE pre-
vention (accepted interventions: 1,631; percentage of 
total accepted interventions: 11.7%), resource utiliza-
tion (628; 4.5%), individualization of patient care (6,122; 
43.8%), prophylaxis (24; 0.2%), hands-on care (3,533; 
25.3%), and administrative/supportive tasks (2,046; 
14.6%). The most frequent interventions were dosage 
adjustments in patients not receiving continuous renal 
replacement therapy (CRRT; accepted interventions 
2,207; percentage of accepted interventions: 15.8%), ini-
tiation of nonantimicrobial therapy (1,705; 12.2%), anti-
microbial therapy initiation and streamlining (1,375; 
9.8%), and bedside monitoring (1,207; 8.6%). The least 
frequently accepted interventions were rejection of a 
restricted medication (percentage accepted: 84.6%), 
antivenin stewardship (87.5%), and medication recon-
ciliation resulting in minor ADE prevention (88.7%). 
Interventions from the five intervention categories with 
the highest quality of evidence totaled 1,564 (11.2% of 
accepted interventions) (Table 2).
The potential CA generated from pharmacist rec-
ommendations totaled $7,531,862 in six sections: ADE 
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prevention ($2,225,049; percentage of CA: 29.5%), 
resource utilization ($310,582; 4.1%), individualiza-
tion of patient care ($1,787,170; 23.7%), prophylaxis 
($22,804; 0.3%), hands-on care ($2,836,811; 37.7%), 
and administrative/supportive ($342,881; 4.6%). The 
areas of greatest CA were major ADE prevention 
($1,232,561; 16.4%), antimicrobial therapy initiation 
and streamlining ($846,244; 11.2%), and blood factor 
stewardship ($683,590; 9.1%). CA from the five inter-
vention categories with the highest quality of evidence 
totaled $959,351 (12.7% of CA from all accepted inter-
ventions) (Table 2).
Average potential CA from accepted interven-
tions was $539 per intervention, $876 per patient, and 
$8,214 per EM pharmacist shift. The annualized po-
tential CA from an EM pharmacist was $1,971,262. 
The potential monetary CA to pharmacist salary ratio 
was $10.6:1. When considering the sensitivity analysis 
of accepted interventions from the five most validated 
intervention categories, average potential CA was 
$613 per intervention, $112 per patient each day, and 
$1,046.18 per ED pharmacist shift. The annualized 
potential CA for an ED pharmacist was $251,084.23. 
The potential monetary CA to pharmacist salary ratio 
was $1.4:1.
DISCUSSION
This is the first multicenter, prospective study to com-
prehensively classify interventions performed by EM 
pharmacists and quantify potential CA generated 
through those interventions. The potential CA gener-
ated from 88 pharmacists over the study period totaled 
over $7.5 million U.S. dollars. This potential CA 
resulted from pharmacists intervening almost 14,000 
times over the course of greater than 8,000 patients. In 
total, 97.2% of these interventions were accepted. EM 
pharmacists generated $8,214 in potential CA per shift 
when all interventions were considered and $1,046 in 
potential CA per shift when only the intervention cat-
egories with the highest quality of evidence were used. 
A significant portion of potential CA resulted from 
interventions that involved hands-on care and pre-
vented ADE development. The monetary CA to phar-
macist salary ratio for EM pharmacists appears to be 
between $1.4:1 and $10.6:1.
Previous studies focusing on the monetary bene-
fit-to-cost ratio of an EM pharmacist have primarily 
focused on a single disease state and have not used a 
TABLE 1. 
Emergency Medicine Pharmacist  
Characteristics
Characteristic
EM Pharmacist  
(n = 88)
Years in practice, n (%)
 ≤ 1 11 (12.5)
 > 1–3 36 (40.9)
 > 3–6 24 (27.3)
 > 6–12 13 (14.8)
 ≥ 12 4 (4.6)
ED visits per year, mean (sd) 75,226 
(32,399)
Institution type, n (%)
 Academic medical center 44 (45.4)
 Community teaching 34 (35.1)
 Community nonteaching 18 (18.6)
 Government 1 (1)
Special populations seen by EM pharmacists, n (%)
 Burn 21 (23.9)
 Pediatrics 49 (55.7)
 Trauma 68 (77.3)
 Stroke 77 (87.5)
Shift duration (hr), n (%)
 8 3,272 (43.1)
 10 2,793 (36.8)
 12 1,117 (14.7)
 Other 412 (5.4)
Shifts worked, median (IQR) 17 (6–20)
Direct patient care duration  
per shift (hr), median (IQR)
6 (4–8)
Prospective order verification duration 
per shift (hr), median (IQR)
5.5 (1–9)
Multidisciplinary clinical services  
rounded with each shift, n (%)
 0 4,948 (82.6)
 1 569 (9.5)
 2 37 (0.6)
 3 367 (6.1)
 4 or more 68 (1.1)




Emergency Severity Index, patients with accepted 
interventions, n (%)
 1 419 (9.2)
 2 1,631 (35.7)
 3 1,841 (40.3)
 4 507 (11.1)
 5 168 (3.7)
ED = emergency department, IQR = interquartile range.
Original Clinical Report
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TABLE 2. 









Section 1: Adverse drug event prevention 1,631 95.0 2,225,049
 Major ADE preventionc 368 97.9 1,232,561
 Minor ADE preventionc 398 96.6 154,631
 Medication reconciliation resulting in major ADE 
preventionc
168 98.8 568,224
 Medication reconciliation resulting in minor ADE 
preventionc
456 88.7 182,565
 Recommend laboratory monitoringd 241 98.8 93,633
Section 2: Resource utilization 628 96.2 310,582
 Preventing unnecessary labs and/or testsd 47 100 18,260
 Prevention of inappropriate screening of heparin-
induced thrombocytopeniab
0 — 0
 Medication route: IV to oral conversionb 169 92.9 10,007
 Medication route: hypertensive crisis managementb 4 100 81,340
 Medication route: resolving shock managementc 2 100 149
 Discontinuation of clinically unwarranted therapyc 317 97.2 21,686
 Prevention of unnecessary high-cost medicationd 89 96.7 179,140
Section 3: Individualization of patient care 6,122 98.1 1,787,170
 Dosage adjustment: continuous renal replacement 
therapyc
4 100 10,187
 Dosage adjustment: no continuous renal replace-
ment therapyc
2,207 98.2 371,681
 Antimicrobial therapy initiation and streamlininga 1,375 97.6 846,244
 Anticoagulant therapy managementc 249 97.3 174,006
 Initiation of nonantimicrobial therapyc 1,705 98.3 287,139
 Antimicrobial pharmacokinetic evaluationc 581 98.5 97,846
 Total parenteral nutrition managementc 1 100 67
Section 4: Prophylaxis 24 100 22,804
 Change venous thromboembolism prophylaxis to 
most appropriate agentb
13 100 252
 Initiation of venous thromboembolism prophylaxisb 3 100 21,508
 Initiation of stress ulcer prophylaxisc 7 100 397
(Continued )
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comprehensive framework of interventions to capture 
CA (8, 9, 20–23). These studies were limited by their 
single center nature, focused on a relatively limited 
number of interventions, and were not based on an 
evidence-based framework. As such, this current study 
adds substantially to the literature to support the role 
of the EM pharmacist as a member of the multidisci-
plinary team.
 Initiation of ventilator associated pneumonia prophy-
laxis with chlorhexidinec
1 100 647
Section 5: Hands-on care 3,533 97.4 2,836,811
 Bedside monitoringd 1,207 97.7 468,944
 Emergency code blue participationc 313 96.9 481,253
 Rapid response team participationc 408 96.2 68,711
 Emergency code stroke participationc 343 95.8 233,809
 Emergency code sepsis participationc 129 98.5 204,453
 Blood factor stewardshipc 71 97.3 683,590
 Emergency procedural sedation or rapid sequence 
intubation participationc
389 98.7 107,889
 Medication teaching or discharge educationc 373 98.9 255,650
 Culture follow-up after emergency department dis-
charged
330 97.1 226,179
 Antivenin stewardshipc 7 87.5 106,333
Section 6: Administrative and supportive tasks 2,046 98.6 342,881
 Drug information consultationc 1,154 97.8 130,494
 Drug information consultation: toxicology specificc 142 98.6 60,270
 Patient own medication evaluationd 239 100 92,856
 Therapeutic interchangec 221 98.7 12,058
 Pharmacist provided drug protocol management 
pursuant to collaborative practice agreementc
262 99.6 28,644
 Rejection of a restricted medicationc 22 84.6 18,559
Total 13,984 97.2 7,531,862
ADE = adverse drug event.
aLevel of evidence IB.
bLevel of evidence IIA.
cLevel of evidence III.
dLevel of evidence IV.
Values presented as cost avoidance in 2019 U.S. dollars (percentage of interventions accepted in section or subsection).
TABLE 2. (Continued). 
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The most common types of intervention made 
by EM pharmacists were in the individualization of 
patient care category, accounting for nearly 44% of 
interventions and 24% of CA. The most frequent inter-
ventions were dosage adjustments in patients not re-
ceiving CRRT, initiation of nonantimicrobial therapy, 
and antimicrobial therapy initiation and streamlin-
ing. Pharmacists are able to intervene on a wide array 
of interventions, including dosing of medications 
based on a number of patient-specific factors such as 
age, weight, route of administration, and renal func-
tion (4). Pharmacists also play an important role in 
antimicrobial stewardship, demonstrating improved 
guideline adherence and antimicrobial selection, 
and decreasing the need for follow-up to change or 
prescribe antimicrobials (24, 25). Specifically, EM 
pharmacists have demonstrated an improvement 
in prescribing practices for community-acquired 
pneumonia and intra-abdominal infections (26). 
EM pharmacists likely had less frequent exposure to 
patients at high risk of medications being under- or 
over-dosed than the ICU but more than other inpa-
tient areas because initial doses provided in the ED 
are less likely to exceed a toxic threshold and very few 
patients are provided CRRT in the ED (27).
EM pharmacists were very involved in the pro-
vision of hands-on care to emergently ill patients. 
Almost 25% of interventions and approximately 38% 
of CA resulted from these activities. Pharmacists 
participated in emergency code blue (i.e., cardiac 
arrest) response, which has been shown to improve 
compliance with advanced cardiac life support 
guidelines (23, 28). Additionally, EM pharmacists 
were highly active in acute stroke management, 
which frequently reduces door-to-needle times and 
increases the proportion of patients who are eligible 
to receive a thrombolytic if other criteria are met (22, 
29). Finally, blood factor stewardship was the third-
largest category of CA for EM pharmacists, ensuring 
appropriate use of blood factor products and dosages 
are achieved (30, 31). These activities have demon-
strated a reduction in time to hemostasis and subse-
quent reduction in length of stay (21).
Almost one-third (30%) of interventions performed 
by EM pharmacists prevented or mitigated ADE devel-
opment. Major ADE prevention provided the largest 
amount of CA of all interventions. Many of the ADEs 
prevented by EM pharmacists were likely because of 
the lack of available data and velocity at which new data 
are being generated and available for acting on in the 
ED (32, 33). These results build on previous findings 
from a landmark study in which a 66% relative risk re-
duction in ADEs was generated from adding pharma-
cists to interdisciplinary healthcare teams (34). In our 
study, in addition to preventing over 1,600 ADEs dur-
ing patient care activities, over 600 additional ADEs 
were prevented following medication reconciliation. 
For ED patients, determining appropriate medication 
dosages, time of last dose, presence of medications that 
may result in withdrawal symptoms, and duplicative 
therapies are the most common interventions that pre-
vent an ADE (35, 36).
EM pharmacists were infrequently reporting 
interventions supporting more efficient utilization 
of healthcare resources, ensuring prophylaxis was 
provided for patients at risk for preventable compli-
cations of critical illness, and performing adminis-
trative and supportive tasks. These findings are not 
surprising given these opportunities occur less fre-
quently in ED patients, who are commonly being 
stabilized prior to admission than in already hos-
pitalized patients (27). Many of the interventions 
in these sections may not occur until day 2 or 3 of 
hospitalization, including eliminating therapies, 
changing from IV to oral dosage forms, or resolving 
shock (20, 37, 38).
Major strengths of our study include the prospec-
tive design and data collection, multicenter nature, 
large sample size, and use of an evidence-based and 
previously published framework to categorize and 
monetize CA associated with interventions ED and 
ICU pharmacists could perform. Based on our de-
sign, there are important limitations to note that 
have the potential to both over- and under-estimate 
the CA. First, while 88 EM pharmacists were in-
cluded, these results may not be generalizable to all 
EM or non-EM pharmacists and EDs due to possible 
selection bias due to the method of recruitment, 
characteristics of pharmacists likely to participate, 
and the voluntary nature of documenting interven-
tions during each shift. The impact this may have 
had on documentation of interventions is uncer-
tain. Second, documentation of the exact number 
and types of interventions were likely incomplete as 
prospective, real time data collection was performed 
and the ED is a dynamic environment that requires 
Rech et al
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a pharmacist’s attention to move between multiple 
patients and activities. Additionally, interventions 
not included in the published framework were not 
included in this study. However, interventions that 
may not have been documented are likely offset by 
interventions that might otherwise have been imple-
mented at a later point in time by another member 
of the healthcare team. Downstream clinical deci-
sions that reversed a previous pharmacist interven-
tion, appropriateness of initial interventions, and 
reasons for interventions not being accepted were 
not collected. In contrast, a potential bias for more 
frequently documenting accepted interventions 
or inflating interventions performed theoretically 
exists. Pharmacists could record interventions in a 
nonconsecutive manner at their discretion, which 
may have bias the study results. Although the study 
group lacked nonpharmacist collaborators, attempts 
to reduce this bias using the Hawthorne effect were 
instituted (39). Participating pharmacists were aware 
that all data analysis would be performed without 
the use of identifying information and were edu-
cated on proper identification and documentation 
of interventions prior to study participation. Third, 
while a comprehensive, evidence-based framework 
was used to classify interventions and quantify CA, 
these CA values are imperfect. While some are more 
tangible costs such as medication costs when chang-
ing from IV to oral, other costs such as ADE pre-
vention, are more difficult to assign specific values 
given the unknown probability of the ADE occur-
ring without pharmacists intervention. The interven-
tions in our framework mostly pertain to critically 
ill patients in the ICU and may not capture activi-
ties of EM pharmacists with patients of lower acuity 
(16). The framework is also limited in that several 
studies date back several years and practice has 
evolved significantly since then. Additionally, data 
collection for this study was undertaken before the 
evidence-based framework was published; however, 
we did conduct a pilot to use this framework before 
the multicenter study (15). Because only five inter-
vention categories have CA values that come from 
controlled studies, the results from the sensitivity 
analysis that used only these intervention categories 
was used to anchor the lowest suspected potential 
CA from EM pharmacists, resulting in a substan-
tial decrease in benefit-to-cost ratio; this highlights 
the need for high-quality studies of EM pharmacists’ 
contribution to CA. Furthermore, we were unable to 
assess the impact of indirect CA and benefits, such 
as protocol or order set implementation that drives 
practice changes and may have ‘trickle down’ effects 
on practice beyond an individual pharmacist-patient 
care scenario. Additional factors may have affected 
the quantity, types of interventions and acceptance, 
including interpersonal and professional relation-
ships, patient volume, and complexity during the 
study period. Finally, the impact of the EM phar-
macist on patient-specific outcomes remains to be 
determined and future research should correlate 
pharmacist interventions with patient outcomes like 
mortality and length of stay. Although it is difficult to 
ascertain the exact monetary benefit that any health-
care professional adds to the multidisciplinary team, 
our study suggests that EM pharmacists make a sig-
nificant number of clinical interventions and that the 
potential CA is greater than the salary and benefits of 
an individual pharmacist.
CONCLUSIONS
Pharmacist involvement in the care of patients pre-
senting to the ED results in significant avoidance of 
healthcare costs, particularly in the areas of hands-on 
patient care and ADE prevention. The potential mone-
tary CA to pharmacist salary ratio for EM pharmacists 
is between $1.4:1 and $10.6:1.
 1 Department of Pharmacy, Loyola University Medical Center, 
Maywood, IL.
 2 Department of Emergency Medicine, Loyola University 
Medical Center, Maywood, IL.
 3 Department of Biostatistics, Loyola University, Maywood, IL.
 4 Department of Pharmacy, Ohio State University Medical 
Center, Columbus, OH.
 5 Department of Pharmacy, Rush University Medical Center, 
Chicago, IL.
 6 Department of Internal Medicine, Rush Medical College, 
Chicago, IL.
 7 Department of Pharmacy, Erlanger Medical Center, 
Chattanooga, TN.
 8 Department of Pharmacy, Froedtert Hospital, Milwaukee, WI.
 9 Department of Surgery, Medical College of Wisconsin, 
Milwaukee, WI.
 10 Department of Pharmacy, University of Kentucky HealthCare, 
Lexington, KY.
Original Clinical Report
Critical Care Explorations www.ccejournal.org     9
 11 Department of Pharmacy Practice and Science, University of 
Kentucky College of Pharmacy, Lexington, KY.
PHARM-EM Investigators provided in Supplemental Table 2 
(http://links.lww.com/CCX/A615).
Supplemental digital content is available for this article. Direct 
URL citations appear in the printed text and are provided in the 
HTML and PDF versions of this article on the journal’s website 
(http://journals.lww.com/ccejournal).
The authors have disclosed that they do not have any potential 
conflicts of interest.
For information regarding this article, E-mail: mrech@lumc.edu
REFERENCES
 1. Center for Disease Control and Prevention: FastStats - 
Emergency Department Visits. Natl Hosp Ambul Med Care 
Surv 2011. 2015. Available at: https://www.cdc.gov/nchs/
fastats/emergency-department.htm. Accessed January 28, 
2020
 2. Ortmann MJ, Johnson EG, Jarrell DH, et al: ASHP guide-
lines on emergency medicine pharmacist services. Am J Heal 
Pharm 2021; 78:261–275
 3. Ling JM, Mike LA, Rubin J, et al: Documentation of pharmacist 
interventions in the emergency department. Am J Heal Pharm 
2005; 62:1793–1797
 4. Morgan SR, Acquisto NM, Coralic Z, et al: Clinical pharmacy 
services in the emergency department. Am J Emerg Med 2018; 
36:1727–1732
 5. Pérez-Moreno MA, Rodríguez-Camacho JM, Calderón-
Hernanz B, et al: Clinical relevance of pharmacist interven-
tion in an emergency department. Emerg Med J 2017; 34: 
495–501
 6. Roman C, Edwards G, Dooley M, et al: Roles of the emergency 
medicine pharmacist: A systematic review. Am J Health Syst 
Pharm 2018; 75:796–806
 7. Weant KA, Baker SN: Emergency medicine pharmacists and 
sepsis management. J Pharm Pract 2013; 26:401–405
 8. Lada P, Delgado G Jr: Documentation of pharmacists’ inter-
ventions in an emergency department and associated cost 
avoidance. Am J Health Syst Pharm 2007; 64:63–68
 9. Sin B, Ciaramella C, Stein G, et al: Implementation of an ad-
vanced pharmacy practice model in the emergency depart-
ment. J Pharm Pract 2020; 33:481–490
 10. American College of Emergency Physicians: Clinical 
Pharmacist Services in the Emergency Department. 2015. 
Available at: https://www.acep.org/patient-care/policy-
statements/clinical-pharmacist-services-in-the-emergency-
department/. Accessed January 28, 2020
 11. Eppert HD, Reznek AJ; American Society of Health-System 
Pharmacists: ASHP guidelines on emergency medicine phar-
macist services. Am J Health Syst Pharm 2011; 68:e81–e95
 12. Farmer BM, Hayes BD, Rao R, et al: The role of clinical pharmacists 
in the emergency department. J Med Toxicol 2018; 14:114–116
 13. Thomas MC, Acquisto NM, Shirk MB, et al: A national survey 
of emergency pharmacy practice in the United States. Am J 
Heal Pharm 2016; 73:386–394
 14. Aldridge VE, Park HK, Bounthavong M, et al: Implementing 
a comprehensive, 24-hour emergency department pharmacy 
program. Am J Heal Pharm 2009; 66:1943–1947
 15. Hammond DA, Flowers HJC, Meena N, et al: Cost avoidance 
associated with clinical pharmacist presence in a medical in-
tensive care unit. J Am Coll Clin Pharm 2019; 2:610–615
 16. Hammond DA, Gurnani PK, Flannery AH, et al: Scoping review 
of interventions associated with cost avoidance able to be per-
formed in the intensive care unit and emergency department. 
Pharmacotherapy 2019; 39:215–231
 17. Harris PA, Taylor R, Minor BL, et al; REDCap Consortium: The 
REDCap consortium: Building an international community of 
software platform partners. J Biomed Inform 2019; 95:103208
 18. Alonso-Coello P, Oxman AD, Moberg J, et al; GRADE Working 
Group: GRADE Evidence to decision (EtD) frameworks: A 
systematic and transparent approach to making well informed 
healthcare choices. 2: Clinical practice guidelines. BMJ 2016; 
353:i2089
 19. U.S. Bureau of Labor Statistics: CPI-All Urban Consumers (Current 
Series) - Help and Information. 2018. Available at: https://www.
bls.gov/ooh/healthcare/pharmacists.htm. Accessed January 30, 
2020
 20. Bailey TC, Dunagan WC, Kahn M, et al: A randomized, prospec-
tive evaluation of an interventional program to discontinue in-
travenous antibiotics at two tertiary care teaching institutions. 
Pharmacotherapy 1997; 17:277–281
 21. Masic D, Hidalgo DC, Kuhrau S, et al: Pharmacist presence 
decreases time to prothrombin complex concentrate in emer-
gency department patients with life-threatening bleeding and 
urgent procedures. J Emerg Med 2019; 57:620–628
 22. Rech MA, Bennett S, Donahey E: Pharmacist participation in 
acute ischemic stroke decreases door-to-needle time to re-
combinant tissue plasminogen activator. Ann Pharmacother 
2017; 51:1084–1089
 23. McAllister MW, Chestnutt JG: Improved outcomes and cost 
savings associated with pharmacist presence in the emer-
gency department. Hosp Pharm 2017; 52:433–437
 24. Fay LN, Wolf LM, Brandt KL, et al: Pharmacist-led antimi-
crobial stewardship program in an urgent care setting. Am J 
Health Syst Pharm 2019; 76:175–181
 25. Wu JY, Balmat R, Kahle ML, et al: Evaluation of a health sys-
tem-wide pharmacist-driven emergency department labora-
tory follow-up and antimicrobial management program. Am J 
Emerg Med 2020; 38:2591–2595
 26. Kulwicki BD, Brandt KL, Wolf LM, et al: Impact of an emer-
gency medicine pharmacist on empiric antibiotic prescribing 
for pneumonia and intra-abdominal infections. Am J Emerg 
Med 2019; 37:839–844
 27. Hammond D, Adams W, Flannery A, et al: PHarmacist avoid-
ance or reductions in medical costs in CRITically ill patients: 
PHARM-CRIT study. Crit Care Med 2020; 48:22
Original Clinical Report
Critical Care Explorations www.ccejournal.org     10
 28. Draper HM, Eppert JA: Association of pharmacist presence on 
compliance with advanced cardiac life support guidelines during 
in-hospital cardiac arrest. Ann Pharmacother 2008; 42:469–474
 29. Montgomery K, Hall AB, Keriazes G: Impact of an emergency 
medicine pharmacist on time to thrombolysis in acute ischemic 
stroke. Am J Emerg Med 2016; 34:1997–1999
 30. Trueg AO, Lowe C, Kiel PJ: Clinical outcomes of a pharmacy-
led blood factor stewardship program. Am J Ther 2017; 
24:e643–e647
 31. Amerine LB, Chen SL, Daniels R, et al: Impact of an innovative 
blood factor stewardship program on drug expense and pa-
tient care. Am J Health Syst Pharm 2015; 72:1579–1584
 32. Goienetxea Uriarte A, Ruiz Zúñiga E, Urenda Moris M, et al: 
How can decision makers be supported in the improvement 
of an emergency department? A simulation, optimization and 
data mining approach. Oper Res Heal Care 2017; 15:102–122
 33. Ebrahimian A, Hashemi-Amrei SH, Monesan M: Exploring fac-
tors affecting the emergency specialists’ decision-making in 
case of emergencies in patients. Crit Care Res Pract 2018; 
2018:9579807
 34. Leape LL, Cullen DJ, Clapp MD, et al: Pharmacist participation 
on physician rounds and adverse drug events in the intensive 
care unit. JAMA 1999; 282:267–270
 35. Tully AP, Hammond DA, Li C, et al: Evaluation of medication 
errors at the transition of care from an ICU to non-ICU loca-
tion. Crit Care Med 2019; 47:543–549
 36. Jain U: How-to Guide: Prevent Adverse Drug Events by 
Implementing Medication Reconciliation. 2011. Available at: 
www.ihi.org. Accessed January 30, 2020
 37. Cyriac JM, James E: Switch over from intravenous to oral 
therapy: A concise overview. J Pharmacol Pharmacother 2014; 
5:83–87
 38. Shrayteh ZM, Rahal MK, Malaeb DN: Practice of switch from 
intravenous to oral antibiotics. Springerplus 2014; 3:717
 39. Sedgwick P, Greenwood N: Understanding the Hawthorne 
effect. BMJ 2015; 351:h4672
